तुलना करने के लिए मीट्रिक्स | BPTSY | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधBPTSYपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −2.1x | −2.6x | −0.2x | |
PEG अनुपात | −0.02 | −0.03 | 0.00 | |
क़ीमत/बुक | −2.2x | 0.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 9.0x | 2.8x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 210.9% | 60.9% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.3% | 9.5% | अनलॉक करें |
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company’s lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.